The Journal of Nuclear Medicine - JNM’s Post

Efficacy and toxicity of ¹⁷⁷Lu-PSMA-617 for mCRPC: Results from the U.S. expanded-access program and comparisons with phase 3 VISION data. https://ow.ly/wkCn50Txxhc #NuclearMedicine #ProstateCancer

¹⁸F-FAPI PET/CT parameters after treatment and their changes from baseline can predict the pathologic response to nCC in LA-ESCC participants. https://ow.ly/uc6050Txxeb #MolecularImaging #EsophagealCancer #MedicalImaging

A triple-tracer imaging strategy can be exploited to detect intrapatient intermetastatic heterogeneity, helping to guide biopsy and personalize management of advanced #ProstateCancer. https://ow.ly/KIfw50Txx8l #NuclearMedicine #PETscan

Best patient care practices for administering PSMA-targeted radiopharmaceutical therapy. https://ow.ly/yfKP50TECMi #RPTherapy #NuclearMedicine #ProstateCancer

In patients with well-differentiated grade 2 and 3 GEP NETs, dual-tracer (⁶⁸Ga-DOTATATE and ¹⁸F-FDG) PET frequently impacts patient management. https://ow.ly/iB7p50TrUMq #NuclearMedicine #NeuroendocrineTumor #PETscan

Challenges with ¹⁷⁷Lu-PSMA-617 radiopharmaceutical therapy in clinical practice. https://ow.ly/4ENr50TrUI2 #NuclearMedicine #ProstateCancer #RPTherapy

Reimagining biologically adapted somatostatin receptor–targeted radionuclide therapy: https://ow.ly/AFMR50TrUAy #NuclearMedicine #RPTherapy #Cancer

Is the clinical application of CXCR4 imaging in the diagnosis and management of primary #aldosteronism really happening? https://ow.ly/FrHS50TrUtX #NuclearMedicine #MedicalImaging

¹⁷⁷Lu-PSMA-617 showed antitumor activity and a favorable toxicity profile for patients with PSMA-positive mCRPC in a real-world setting. https://ow.ly/UZPH50TrUn3 #NuclearMedicine #ProstateCancer #RPTherapy

Navigating the future of #ProstateCancer care: AI-driven imaging and #theranostics through the lens of RELAINCE. https://ow.ly/vPtT50Tfna1 #NuclearMedicine